nach oben

Erschienen in:

25.07.2023 | Original Article

Is unicentric familial papillary thyroid microcarcinoma different from multicentric?

verfasst von: A. Ríos, J. Ruiz-Pardo, A. Balaguer-Román, J. A. Puñal, P. Moreno, E. Mercader, E. Ferrero, M. A. Morlán, J. Martín, M. Durán, J. M. Bravo, D. Casanova, M. P. Salvador-Egea, N. M. Torregrosa, A. Exposito-Rodríguez, G. Martínez-Fernández, A. M. Carrión, O. Vidal, F. Herrera, G. Ruiz-Merino, J. M. Rodríguez

Erschienen in: Endocrine | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Familial papillary thyroid microcarcinoma (FPTMC) appears to be more aggressive than sporadic papillary thyroid microcarcinoma (SPTMC). However, there are authors who indicate that unicentric FPTMC has a similar prognosis to SPTMC. The objective is to analyze whether unicentric FPTMC has a better prognosis than multicentric FPTMC.

Design and methods

Type of study: National multicenter longitudinal analytical observational study. Study population: Patients with FPTMC. Study groups: Two groups were compared: Group A (unicentric FPTMC) vs. Group B (multicentric FPTMC). Study variables: It is analyzed whether between the groups there are: a) differentiating characteristics; and b) prognostic differences. Statistical analysis: Cox regression analysis and survival analysis.

Results

Ninety-four patients were included, 44% (n = 41) with unicentric FPTMC and 56% (n = 53) with multicentric FPTMC. No differences were observed between the groups according to socio-familial, clinical or histological variables. In the group B a more aggressive treatment was performed, with higher frequency of total thyroidectomy (99 vs. 78%; p = 0.003), lymph node dissection (41 vs. 15%; p = 0.005) and therapy with radioactive iodine (96 vs. 73%; p = 0.002). Tumor stage was similar in both groups (p = 0.237), with a higher number of T3 cases in the group B (24 vs. 5%; p = 0.009). After a mean follow-up of 90 ± 68.95 months, the oncological results were similar, with a similar disease persistence rate (9 vs. 5%; p = 0.337), disease recurrence rate (21 vs. 8%; p = 0.159) and disease-free survival (p = 0.075).

Conclusions

Unicentric FPTMC should not be considered as a SPTMC due to its prognosis is similar to multicentric FPTMC.

Graphical Abstract

A. Miyauchi, Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J. Surg. 40, 516–22 (2016). https://doi.org/10.1007/s00268-015-3392-yCrossRefPubMedPubMedCentral

A. Ríos, J.M. Rodríguez, D. Navas, A. Cepero, N.M. Torregrosa, M.D. Balsalobre et al. Family screening in familial papillary carcinoma: the early detection of thyroid disease. Ann. Surg. Oncol. 23, 2564–70 (2016). https://doi.org/10.1245/s10434-016-5149-8CrossRefPubMed

M. Capezzone, C. Secchi, N. Fralassi, S. Cantara, L. Brilli, C. Ciuoli et al. Should familial disease be considered as a negative prognostic factor in micropapillary thyroid carcinoma? J. Endocrinol. Invest 42, 1205–13 (2019). https://doi.org/10.1007/s40618-019-01039-0CrossRefPubMed

E.L. Maxwell, F.T. Hall, J.L. Freeman, Familial non‐medullary thyroid cancer: a matched‐case control study. Laryngoscope 114, 2182–6 (2004). https://doi.org/10.1097/01.mlg.0000149454.91005.65CrossRefPubMed

V. Nosé, Familial thyroid cancer: a review. Mod. Pathol. 24, S19–33 (2011). https://doi.org/10.1038/modpathol.2010.147CrossRefPubMed

S. Uchino, S. Noguchi, H. Kawamoto, H. Yamashita, S. Watanabe, H. Yamashita et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J. Surg. 26, 897–902 (2002). https://doi.org/10.1007/s00268-002-6615-yCrossRefPubMed

R.S. Sippel, N.R. Caron, O.H. Clark, An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J. Surg. 31, 924–33 (2007). https://doi.org/10.1007/s00268-006-0847-1CrossRefPubMed

X. Wu, B. Li, C. Zheng, X. He, Predicting factors of central lymph node metastases in patients with unilateral multifocal papillary thyroid microcarcinoma. Gland Surg. 9, 695–701 (2020). https://doi.org/10.21037/gs.2020.03.27CrossRefPubMedPubMedCentral

A.R. Shaha, V.V. Poorten, R.M. Tuttle, Multifocality in papillary thyroid carcinoma-An unresolved controversy. Eur. J. Surg. Oncol. 46, 1777–8 (2020). https://doi.org/10.1016/j.ejso.2020.06.026CrossRefPubMed

10.

J.W. Feng, Z. Qu, A.C. Qin, H. Pan, J. Ye, Y. Jiang, Significance of multifocality in papillary thyroid carcinoma. Eur. J. Surg. Oncol. 46, 1820–8 (2020). https://doi.org/10.1016/j.ejso.2020.06.015CrossRefPubMed

11.

C.R. Lee, S. Park, S.W. Kang, J. Lee, J.J. Jeong, K.H. Nam et al. Is familial papillary thyroid microcarcinoma more aggressive than sporadic form? Ann. Surg. Treat. Res 92, 129–35 (2017). https://doi.org/10.4174/astr.2017.92.3.129CrossRefPubMedPubMedCentral

12.

G. Lupoli, G. Vitale, M. Caraglia, M.R. Fittipaldi, A. Abbruzzese, P. Tagliaferri et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 353, 637–9 (1999). https://doi.org/10.1016/S0140-6736(98)08004-0CrossRefPubMed

13.

S. Lei, D. Wang, J. Ge, H. Liu, D. Zhao, G. Li, Z. Ding, Single-center study of familial papillary thyroid cancer in China: surgical considerations. World J. Surg. Oncol. 13, 115 (2015). https://doi.org/10.1186/s12957-015-0519-4CrossRefPubMedPubMedCentral

14.

T.Y. Sung, Y.M. Lee, J.H. Yoon, K.W. Chung, S.J. Hong, Surgical management of familial papillary thyroid microcarcinoma: a single institution study of 94 cases. World J. Surg. 39, 1930–5 (2015). https://doi.org/10.1007/s00268-015-3064-yCrossRefPubMed

15.

J. Cao, C. Chen, C. Chen, Q.L. Wang, M.H. Ge, Clinicopathological features and prognosis of familial papillary thyroid carcinoma–a large-scale, matched, case-control study. Clin. Endocrinol. 84, 598–606 (2016). https://doi.org/10.1111/cen.12859CrossRef

16.

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016). https://doi.org/10.1089/thy.2015.0020CrossRefPubMedPubMedCentral

17.

K.R. Joseph, S. Edirimanne, G.D. Eslick, Multifocality as a prognostic factor in thyroid cancer: a meta-analysis. Int J. Surg. 550, 121–5 (2018). https://doi.org/10.1016/j.ijsu.2017.12.035CrossRef

18.

F. Wang, X. Yu, X. Shen, G. Zhu, Y. Huang, R. Liu, D. Viola, R. Elisei, E. Puxeddu, L. Fugazzola, C. Colombo, B. Jarzab, A. Czarniecka, A.K. Lam, C. Mian, F. Vianello, L. Yip, G. Riesco-Eizaguirre, P. Santisteban, C.J. O’Neill, M.S. Sywak, R. Clifton-Bligh, B. Bendlova, V. Sýkorová, Y. Wang, S. Liu, J. Zhao, S. Zhao, M. Xing, The prognostic value of tumor multifocality in clinical outcomes of papillary thyroid cancer. J. Clin. Endocrinol. Metab. 102, 3241–3250 (2017). https://doi.org/10.1210/jc.2017-00277CrossRefPubMedPubMedCentral

19.

V. Harries, L.Y. Wang, M. McGill, B. Xu, R.M. Tuttle, R.J. Wong et al. Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma? Surgery 167, 10–17 (2020). https://doi.org/10.1016/j.surg.2019.03.031CrossRefPubMed

20.

A. La Greca, B. Xu, R. Ghossein, R.M. Tuttle, M.M. Sabra, Patients with multifocal macroscopic papillary thyroid carcinoma have a low risk of recurrence at early follow-up after total thyroidectomy and radioactive iodine treatment. Eur. Thyroid J. 6, 31–9 (2017). https://doi.org/10.1159/000448752CrossRefPubMed

21.

N. Qu, L. Zhang, Q.H. Ji, Y.X. Zhu, X.Y. Wang, Q. Shen et al. Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer 14, 914–919 (2014). https://doi.org/10.1186/1471-2407-14-914CrossRefPubMedPubMedCentral

22.

Z. Lu, J. Sheng, Y. Zhang, J. Deng, Y. Li, A. Lu et al. Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. J. Pathol. 239, 72–83 (2016). https://doi.org/10.1002/path.4696CrossRefPubMedPubMedCentral

23.

A. Al Afif, B.A. Williams, M.H. Rigby, M.J. Bullock, S.M. Taylor, J. Trites et al. Multifocal papillary thyroid cancer increases the risk of central lymph node metastasis. Thyroid 25, 1008–12 (2015). https://doi.org/10.1089/thy.2015.0130CrossRefPubMed

24.

W.R. Choi, J.L. Roh, G. Gong, K.J. Cho, S.H. Choi, S.Y. Nam et al. Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence. Oral. Oncol. 94, 106–110 (2019). https://doi.org/10.1016/j.oraloncology.2019.05.023CrossRefPubMed

25.

Y. Ito, A. Miyauchi, H. Oda, Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. EJSO 44, 307–315 (2018). https://doi.org/10.1016/j.ejso.2017.03.004CrossRefPubMed

26.

Y.W. Jeon, H.G. Gwak, S.T. Lim, J. Schneider, Y.J. Suh, Long-term prognosis of unilateral and multifocal papillary thyroid microcarcinoma after unilateral lobectomy versus total thyroidectomy. Ann. Surg. Oncol. 26, 2952–2958 (2019). https://doi.org/10.1245/s10434-019-07482-wCrossRefPubMed

27.

J.F. Lin, P.K.C. Jonker, M. Cunich, S.B. Sidhu, L.W. Delbridge, A.R. Glover et al. Surgery alone for papillary thyroid microcarcinoma is less costly and more effective than long term active surveillance. Surgery 167, 110–116 (2020). https://doi.org/10.1016/j.surg.2019.05.078CrossRefPubMed

28.

B. Saravana-Bawan, A. Bajwa, J. Paterson, T. McMullen, Active surveillance of low-risk papillary thyroid cancer: a meta-analysis. Surgery 167, 46–55 (2020). https://doi.org/10.1016/j.surg.2019.03.040CrossRefPubMed

29.

D.I. Stefanova, A. Bose, T.M. Ullmann, J.N. Limberg, B.M. Finnerty, R. Zarnegar et al. Does the ATA risk stratification apply to patients with papillary thyroid microcarcinoma? World J. Surg. 44, 452–460 (2020). https://doi.org/10.1007/s00268-019-05215-4CrossRefPubMed

30.

X. Wang, W. Cheng, J. Li, A. Su, T. Wei, F. Liu et al. Endocrine tumours: familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis. Eur. J. Endocrinol. 172, R253–R262 (2015). https://doi.org/10.1530/EJE-14-0960CrossRefPubMed

Titel: Is unicentric familial papillary thyroid microcarcinoma different from multicentric?
verfasst von: A. Ríos
J. Ruiz-Pardo
A. Balaguer-Román
J. A. Puñal
P. Moreno
E. Mercader
E. Ferrero
M. A. Morlán
J. Martín
M. Durán
J. M. Bravo
D. Casanova
M. P. Salvador-Egea
N. M. Torregrosa
A. Exposito-Rodríguez
G. Martínez-Fernández
A. M. Carrión
O. Vidal
F. Herrera
G. Ruiz-Merino
J. M. Rodríguez
Publikationsdatum: 25.07.2023
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2023
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03455-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Is unicentric familial papillary thyroid microcarcinoma different from multicentric?